BIIB Biogen presents phase 2 celia data at aaic demonstrating meaningful clinical outcomes and robust Tau reduction with diranersen in early

BIIB Biogen presents phase 2 celia data at aaic demonstrating meaningful clinical outcomes and robust Tau reduction with diranersen in early alzheimer’s disease Biogen - to advance diranersen into confirmatory phase 3 development